ClinicalTrials.gov
ClinicalTrials.gov Menu

Role of Greyscale and Power Doppler Sonography in Therapy Monitoring in Early Rheumatoid Arthritis (RA)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00854243
Recruitment Status : Unknown
Verified March 2009 by Cairo University.
Recruitment status was:  Not yet recruiting
First Posted : March 3, 2009
Last Update Posted : March 3, 2009
Sponsor:
Information provided by:
Cairo University

Brief Summary:
The purpose of this study is to evaluate the role of musculoskeletal ultrasound and power Doppler in early therapy monitoring of rheumatoid arthritis patients.

Condition or disease
Rheumatoid Arthritis

Study Type : Observational
Estimated Enrollment : 20 participants
Time Perspective: Prospective
Official Title: Therapy Monitoring in Early Rheumatoid Arthritis: The Role of Greyscale and Power Doppler Sonography A Prospective Study Of 20 Egyptian Rheumatoid Arthritis Patients
Study Start Date : April 2009
Estimated Primary Completion Date : April 2010
Estimated Study Completion Date : April 2010

Resource links provided by the National Library of Medicine

U.S. FDA Resources





Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 50 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
Adult onset Rheumatoia Arthritis patients with a disease duration of less than 3 months
Criteria

Inclusion Criteria:

  • Adults: age at disease onset >18 years and < 50 years
  • Disease duration < 3 month
  • Fulfilling ARA criteria for classification of RA
  • DMARD naive

Exclusion Criteria:

  • Age at diagnosis < 18 years
  • Disease duration > 3 month
  • Previous use of DMARDS
  • Previous use of biologics

Responsible Party: Ghada El-Mardenly, Cairo University
ClinicalTrials.gov Identifier: NCT00854243     History of Changes
Other Study ID Numbers: RA1
First Posted: March 3, 2009    Key Record Dates
Last Update Posted: March 3, 2009
Last Verified: March 2009

Additional relevant MeSH terms:
Arthritis
Arthritis, Rheumatoid
Joint Diseases
Musculoskeletal Diseases
Rheumatic Diseases
Connective Tissue Diseases
Autoimmune Diseases
Immune System Diseases